JY
SGMT icon

Jeff Yass’s Sagimet Biosciences SGMT Stock Holding History

Jeff Yass’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
289,300
+178,300
+161% +$1.21M ﹤0.01% 6232
2026
Q1 		$581K Buy
111,000
+54,500
+96% +$304K ﹤0.01% 9279
2025
Q4 		$334K Sell
56,500
-105,400
-65% -$757K ﹤0.01% 9699
2025
Q3 		$1.11M Buy
161,900
+11,300
+8% +$91.6K ﹤0.01% 7099
2025
Q2 		$1.15M Buy
150,600
+94,800
+170% +$400K ﹤0.01% 7091
2025
Q1 		$182K Buy
55,800
+33,400
+149% +$140K ﹤0.01% 11044
2024
Q4 		$101K Buy
+22,400
New +$113K ﹤0.01% 11340

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jeff Yass's SGMT Position: Q2 2026 in Review

Jeff Yass reduced its Sagimet Biosciences (SGMT) stake by 91% in Q2 2026, selling an estimated $773K and leaving 10,950 shares worth $84.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12602.

Jeff Yass first reported a position in SGMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.08M in Q2 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Jeff Yass held 10,950 shares of Sagimet Biosciences worth $84.6K as of Q2 2026.
  • Jeff Yass sold 113,654 Sagimet Biosciences shares in Q2 2026, an estimated $773K.
  • Sagimet Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12602 holding.
  • Jeff Yass first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 10 quarters since.
  • Jeff Yass's Sagimet Biosciences position peaked at $1.08M in Q2 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.